Norditropin Nordiflex (Somatropin)

Somatropin, the active ingredient in Norditropin Nordiflex, is a human growth hormone presented as a solution for injection for subcutaneous use. It treats growth hormone deficiency and related growth disorders in children and adults.

GNH USA supplies Norditropin Nordiflex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Norditropin Nordiflex is a recombinant human growth hormone used to address conditions characterized by insufficient endogenous growth hormone activity.

- Growth hormone deficiency: promotes linear growth and normalizes IGF‑1 levels. - Turner syndrome: supports increased growth velocity in affected girls. - Chronic renal insufficiency: improves growth parameters in pediatric renal disease. - Prader‑Willi syndrome: enhances growth and body composition. - Idiopathic short stature: increases height velocity in children with unexplained short stature.

Adverse reactions may occur with somatropin therapy and vary in frequency and severity.

Common Side Effects: - Injection site pain or erythema. - Headache. - Joint or muscle pain. - Peripheral edema. - Hyperglycemia. - Fatigue.

Serious or Rare Side Effects: - Intracranial hypertension. - Slipped epiphysis (growth plate injury). - Severe allergic reactions, including anaphylaxis. - Increased intracranial pressure. - Development of neoplasms in predisposed individuals. - Cardiomyopathy.

Clinicians should observe several safety considerations when prescribing somatropin.

- Monitor glucose: patients with diabetes may require tighter glycemic control. - Assess IGF‑1 levels: dose adjustments should be guided by serial IGF‑1 measurements. - Screen for malignancy: avoid use in patients with active cancer. - Evaluate for intracranial hypertension: watch for headaches, visual changes, or vomiting. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Somatropin may interact with other medications, affecting efficacy or safety.

Major Interactions (Avoid): - Concurrent insulin or oral hypoglycemics: increased risk of hypoglycemia. - High‑dose glucocorticoids: may diminish somatropin effectiveness. - Use with other growth hormone products: risk of overdose and adverse effects.

Moderate Interactions (Monitor Closely): - Estrogen therapy: can elevate IGF‑1 levels, requiring dose review. - Thyroid hormone replacement: may need dose adjustment based on thyroid function. - CYP enzyme modulators: generally minimal impact, but monitor clinical response.